Targeting TNFSF4 in the Management of Systemic Lupus Erythematosus

Year : 2024 | Volume : 14 | Issue : 03 | Page : 6 14
    By

    Preeti Shanbhag,

  • Ramdas Bhat,

  1. PG Scholar, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore,, Karnataka, India
  2. Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka, India

Abstract

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that remains a significant challenge for both healthcare providers and researchers. Despite advances in understanding its mechanisms, finding effective therapies is still difficult. This review highlights a potential therapeutic target in SLE research: tumor necrosis factor superfamily member 4 (TNFSF4), also referred to as OX40L. We explore how TNFSF4 contributes to SLE development, looking at its role in immune system regulation and how its dysfunction may lead to disease progression. Current SLE treatments are discussed, highlighting both their strengths and limitations, which underscores the need for new therapeutic approaches. Recent studies targeting the TNFSF4-OX40 pathway have shown potential in managing SLE. We examine both laboratory and clinical research, considering their methods, results, and implications for future work. Early evidence suggests that inhibiting TNFSF4-OX40 interactions might help normalize immune responses in SLE patients, potentially improving their health outcomes. Looking ahead, the TNFSF4-OX40 pathway represents a promising avenue for SLE treatment. Future research should focus on refining these therapies, understanding their long-term effects, and identifying which patients might benefit most. By deepening our understanding of TNFSF4’s role in SLE, we may open the door to more targeted and effective treatments, ultimately improving the lives of those living with this challenging disease.

Keywords: TNFSF4, OX40L, systemic lupus erythematosus (SLE), immune regulation, therapeutic target.

[This article belongs to Research & Reviews : A Journal of Immunology ]

How to cite this article:
Preeti Shanbhag, Ramdas Bhat. Targeting TNFSF4 in the Management of Systemic Lupus Erythematosus. Research & Reviews : A Journal of Immunology. 2024; 14(03):6-14.
How to cite this URL:
Preeti Shanbhag, Ramdas Bhat. Targeting TNFSF4 in the Management of Systemic Lupus Erythematosus. Research & Reviews : A Journal of Immunology. 2024; 14(03):6-14. Available from: https://journals.stmjournals.com/rrjoi/article=2024/view=183229


References

  1. Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326–38.
  2. Kumar R, Kumar A, Saroj U, et al. A cross-sectional study of clinical and laboratory characteristics of systemic lupus erythematosus in tribal region of Jharkhand at RIMS, Ranchi. J Family Med Prim Care. 2022;11(12):7836–41.
  3. Justiz Vaillant AA, Goyal A, Varacallo M, et al. Systemic lupus erythematosus. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.statpearls.com/
  4. Refai RH, Hussein MF, Abdou MH, et al. Environmental risk factors of systemic lupus erythematosus: a case–control study. Sci Rep. 2023;13(1):10219.
  5. Wallace DJ, Gladman DD, et al. Clinical manifestations and diagnosis of systemic lupus erythematosus in adults. UpToDate. Waltham (MA); 2020. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-lupus-erythematosus-in-adults/print
  6. Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci. 2023;24(7):6578.
  7. Thong B, Olsen NJ, et al. Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford). 2016;56(1):1–13.
  8. Dao LTM, Vu TT, Nguyen QT, et al. Current cell therapies for systemic lupus erythematosus. Stem Cells Transl Med. 2024;13(9):859–72.
  9. Fu Y, Lin Q, Zhang ZR, et al. Association of TNFSF4 polymorphisms with systemic lupus erythematosus: a meta-analysis. Adv Rheumatol. 2021;61(1).
  10. Kumar P, Bhattacharya P, Prabhakar BS, et al. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun. 2018;95:77–99.
  11. Paredes JL, Fernandez-Ruiz R, Niewold TB, et al. T Cells in systemic lupus erythematosus. Rheum Dis Clin North Am. 2021;47(3):379–93.
  12. Thapa B, Kato S, Nishizaki D, et al. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024;43(3):1001–13.
  13. Sadrolashrafi K, Guo L, Kikuchi R, et al. An OX-Tra’Ordinary Tale: The role of OX40 and OX40L in atopic dermatitis. Cells. 2024;13(7):587.
  14. Fu N, Xie F, Sun Z, et al. The OX40/OX40L axis regulates T follicular helper cell differentiation: implications for autoimmune diseases. Front Immunol. 2021;12:1–13.
  15. Katarzyna PB, Wiktor S, Ewa D, et al. Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatol Int. 2023;43(8):1395–407.
  16. Téllez Arévalo AM, Quaye A, Rojas-Rodríguez LC, et al. Synthetic pharmacotherapy for systemic lupus erythematosus: potential mechanisms of action, efficacy, and safety. Medicina (Kaunas). 2022;59(1):56.
  17. Athanassiou P, Athanassiou L, et al. Current treatment approach, emerging therapies, and new horizons in systemic lupus erythematosus. Life (Basel). 2023;13(7):1496.
  18. van Schaik M, Arends EJ, Soonawala D, et al. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials. 2022;23(1):939.
  19. Tanaka Y, et al. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open. 2023;9(3).
  20. Nikolopoulos D, Parodis I, et al. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023;10:1217147.
  21. Li NL, Birmingham DJ, Rovin BH, et al. Expanding the role of complement therapies: the case for lupus nephritis. J Clin Med. 2021;10(4):626.
  22. Ghannam K, Martinez Gamboa L, Kedor C, et al. Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis. RMD Open. 2020;6(3).
  23. Fenton KA, Pedersen HL, et al. Advanced methods and novel biomarkers in autoimmune diseases ‑ a review of the recent years’ progress in systemic lupus erythematosus. Front Med (Lausanne). 2023;10:1–14.
  24. Gerasimova EV, Tabakov DV, Gerasimova DA, et al. Activation markers on B and T cells and immune checkpoints in autoimmune rheumatic diseases. Int J Mol Sci. 2022;23(15):8656.
  25. Cortini A, Ellinghaus U, Malik TH, et al. B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis. Ann Rheum Dis. 2017;76(12):2095–103.
  26. Baumjohann D, Heikenwälder M, et al. OX40/OX40L axis as a therapeutic target in autoimmunity and inflammation. Nat Rev Drug Discov. 2020;19(3):173–189.
  27. Allen ME, Rus V, Szeto GL, et al. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021;27(2):152–71.
  28. Choi MY, Costenbader KH, et al. Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development. Front Immunol. 2022;13:890522.
  29. von Hofsten S, Fenton KA, Pedersen HL, et al. Human and murine toll-like receptor-driven disease in systemic lupus erythematosus. Int J Mol Sci. 2024;25(10):5351.
  30. Croft M, Siegel RM, et al. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217–33.
  31. Obasanmi G, Lois N, Armstrong D, et al. Peripheral blood mononuclear cells from patients with type 1 diabetes and diabetic retinopathy produce higher levels of IL-17A, IL-10, and IL-6 and lower levels of IFN-γ—A pilot study. Cells. 2023;12(3):467.
  32. Karrar S, Cunninghame Graham DS, et al. Review: Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018;70(4):496–507.
  33. Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther. 2022;111(5):1121–32.
  34. Nicholson SM, Casey KA, Gunsior M, et al. The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020;177(5):1061–76.
  35. Ali O, Wang L, Xu W, et al. Duration of clinical efficacy following treatment with VIB4920 in subjects with moderate to severe rheumatoid arthritis. Ann Rheum Dis. 2021;80(Suppl 1):67.
Regular Issue Subscription Review Article
Volume 14
Issue 03
Received 13/09/2024
Accepted 04/10/2024
Published 15/11/2024
187

Login


My IP

PlumX Metrics